RELX Stock Price Rises, Institutional Investors Adjust Holdings

Business by 2FIRSTS.ai
Dec.28.2023
RELX Stock Price Rises, Institutional Investors Adjust Holdings
RELX Technology Inc.'s stock price rose 4.8% in midday trading on December 27, with institutional investors adjusting their holdings.

According to financial market analysis on December 27th, RELX Technology Inc. (NYSE: RLX) saw a 4.8% increase in its stock price during midday trading. The company's shares briefly rose to $2.00 and finally closed at $1.98, with approximately 4,474,611 shares changing hands, representing a 47% decrease from the average daily trading volume of 8,412,278 shares.

 

In recent times, there have been adjustments in the ownership of RELX Technology stocks by institutional investors and hedge funds.

 

PNC Financial Services Group Inc. acquired stock shares valued at approximately $27,000, while Vanguard Personalized Indexing Management LLC purchased shares worth around $37,000 in the third quarter. In the first quarter, Apollon Wealth Management LLC acquired stock shares valued at approximately $38,000. Clear Street Markets LLC made a new purchase in the fourth quarter, acquiring stock shares valued at around $40,000. Lastly, Mariner LLC purchased stock shares worth approximately $47,000 in the third quarter.

 

Currently, institutional investors and hedge funds hold 22.68% of RELX Technology company's stocks.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
The U.S. Food and Drug Administration has told vape manufacturer Fontem US that it does not presently intend to take enforcement action against the company’s Zone nicotine pouches while litigation over the agency’s handling of the application remains unresolved.
Apr.07 by 2FIRSTS.ai
Special Report| War continues to shape the Ukrainian tobacco market
Special Report| War continues to shape the Ukrainian tobacco market
Four years into the war, Ukraine’s tobacco market is being reshaped by stress-driven consumption, tax pressure, youth e-cigarette use and a growing illicit segment. Surveys point to rising tobacco and nicotine product use, while higher excise duties and shadow trade are adding new complexity to the market.
Apr.17
Japan to Raise Heated Tobacco Prices From April; BAT Japan Keeps Prices Unchanged for 38 glo Tobacco Stick Products
Japan to Raise Heated Tobacco Prices From April; BAT Japan Keeps Prices Unchanged for 38 glo Tobacco Stick Products
Japan will implement price increases centered on heated tobacco products from April 1, 2026, following a tobacco tax hike. BAT Japan has decided to keep current prices unchanged for 38 glo-compatible tobacco stick products across the Velo, neo, Lucky Strike, and Kent lines.
Mar.30 by 2FIRSTS.ai
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s PSOE files motion to curb vaping and nicotine pouches, restricting sales channels and banning online sales
Spain’s Socialist Party (PSOE) has registered a non-legislative motion (PNL) in Congress seeking to curb the use of vapes and nicotine pouches by restricting sales to authorised channels and banning sales online and in non-specialist shops. The proposal says the current “lack of control” in commercialisation facilitates tax evasion and breaches existing health and environmental rules.
Mar.03 by 2FIRSTS.ai
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai